NASDAQ$VERA
Vera Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported business highlights and financial results for the first quarter ended March 31, 2024.
Vera Therapeutics reported positive 72-week data from the Phase 2b ORIGIN clinical trial and completed a $287.5 million financing. The company's cash and equivalents totaled $403.7 million as of March 31, 2024. Net loss for the quarter was $28.4 million, or $0.56 per share.
- Presented positive 72-week data from the ORIGIN Phase 2b trial of atacicept in IgAN, showing consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment.
- Expanded management team with key appointments, including Robert M. Brenner, M.D., as Chief Medical Officer and William D. Turner as Chief Development Officer.
- Actively adding sites and enrolling pivotal Phase 3 ORIGIN 3 study of atacicept for the treatment of IgAN.
- Completed $287.5 million financing in February, strengthening the Company’s balance sheet with $403.7 million in cash and equivalents as of March 31, 2024, extending the Company’s expected cash runway through potential approval and commercial launch.
Headline financials
Revenue & EPS history
Vera · Revenue · Quarterly
$935K
Forward guidance
Vera Therapeutics anticipates several milestones in 2024, including presentations at the European Renal Association Congress (ERA24) and the release of topline 96-week data from the ORIGIN Ph 2b clinical trial. The company also expects to complete enrollment in the pivotal Phase 3 ORIGIN 3 trial in Q3 2024 and announce preliminary data in the first half of 2025.
Tailwinds
- Two abstracts selected for oral presentations – including “Best-Ranked Abstract” – at the 61st European Renal Association Congress (ERA24) on May 25, 2024
- Plan to present topline 96-week data from ORIGIN Ph 2b clinical trial of atacicept in IgAN in the fourth quarter of 2024
- Pivotal Phase 3 ORIGIN 3 trial estimated to complete enrollment in the third quarter of 2024
- On track to announced preliminary data in the first half of 2025
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
+0.2%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+7.2%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+15.6%
Q1 2022
Best reaction
-13.5%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | +0.3% | -11.8% | |
| Q4 2025 | +1.5% | -5.7% | -6.8% | |
| Q3 2025 | +4.6% | +23.3% | +86.3% | |
| Q1 2025 | -13.5% | -15.0% | +20.0% | |
| Q4 2024 | +1.3% | -0.7% | -22.1% | |
| Q3 2024 | +0.3% | +1.3% | +1.1% | |
| Q2 2024 | +0.9% | +6.5% | +4.3% | |
| Q1 2024 | -8.1% | -9.1% | -14.3% | |
| Q4 2023 | -1.3% | -5.2% | -12.5% | |
| Q3 2023 | +5.4% | +18.2% | +18.9% | |
| Q2 2023 | -0.1% | -4.3% | -0.1% | |
| Q1 2023 | -1.7% | +0.0% | +0.9% | |
| Q4 2022 | +4.4% | +6.3% | -14.2% | |
| Q3 2022 | -3.2% | -3.8% | -2.1% | |
| Q2 2022 | +7.8% | +20.6% | +11.4% | |
| Q1 2022 | +15.6% | +11.4% | -8.5% | |
| Q4 2021 | +10.2% | +11.2% | +5.2% | |
| Q3 2021 | -11.6% | -7.1% | -3.3% | |
| Q2 2021 | +0.3% | +11.6% | +80.6% | |
| Q1 2021 | -7.6% | -13.6% | +11.0% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro